Organigram Holdings Inc. (TSE:OGI - Free Report) - Stock analysts at Alliance Global Partners dropped their Q4 2024 earnings estimates for shares of Organigram in a research report issued on Monday, December 9th. Alliance Global Partners analyst A. Grey now anticipates that the company will earn ($0.03) per share for the quarter, down from their previous forecast of ($0.02). The consensus estimate for Organigram's current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram's Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.03) EPS.
Separately, Canaccord Genuity Group decreased their target price on Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating for the company in a research report on Monday.
Check Out Our Latest Research Report on Organigram
Organigram Trading Down 0.5 %
Shares of OGI traded down C$0.01 during mid-day trading on Wednesday, reaching C$2.16. 117,027 shares of the company's stock traded hands, compared to its average volume of 295,290. The company has a debt-to-equity ratio of 1.13, a current ratio of 6.95 and a quick ratio of 2.62. The stock's 50-day moving average is C$2.29 and its two-hundred day moving average is C$2.31. Organigram has a 12 month low of C$1.61 and a 12 month high of C$3.95. The stock has a market cap of C$234.51 million, a P/E ratio of -0.86, a P/E/G ratio of 0.42 and a beta of 1.13.
Insider Buying and Selling
In related news, Senior Officer Paolo De Luca sold 12,014 shares of the stock in a transaction on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total transaction of C$30,275.28. 31.32% of the stock is currently owned by corporate insiders.
About Organigram
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Recommended Stories
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
